在炎症性肠道疾病中使用抗氧化剂疗法:我们已经走了多远,还有多远?
Lylian Ellen Militão Dos Santos Xavier1, Thays Cristhyna Guimaraes Reis2, Amylly Sanuelly da Paz Martins3
1Postgraduate Degree in Nutrition (PPGNUT), Federal University of Alagoas (UFAL), Maceió 57072-970, AL, Brazil.
Antioxidants (Basel, Switzerland)
|November 27, 2024
概括
抗氧化剂通过对抗氧化压力,对炎症性肠病 (IBD) 有希望. 然而,需要更多的人类研究来证实它们在IBD治疗中的治疗益处.
科学领域:
- 胃肠病学和肝病学
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 是一个严重的公共卫生问题,其起源复杂,常规治疗选择有限.
- 氧化应激越来越被认为是IBD病变的关键因素.
- 抗氧化剂正在被探索为IBD的潜在治疗剂.
研究的目的:
- 系统地审查有关抗氧化剂在炎症性肠病 (IBD) 中的作用的现有文献.
- 在IBD模型中分析各种抗氧化剂对氧化应激标志物的影响.
- 确定有关IBD抗氧化疗法的研究缺口.
主要方法:
- 进行了2015年7月至2024年6月期间发表的研究的系统审查.
- 搜索的数据库包括MEDLINE,Cochrane,科学网络,EMBASE和Scopus.
- 纳入标准侧重于小鼠模型和人类临床试验,评估IBD中的抗氧化剂和氧化应激,最终包含了368篇文章.
主要成果:
- 在IBD中观察到氧化应激和炎症之间的强烈关联,特别是涉及NF-κB和Nrf2通路.
- 多和植物衍生化合物是研究最多的抗氧化剂 (70.3%).
- 脂质过氧化是评估的最常见的氧化损伤形式,而蛋白质损伤很少被研究. 抗氧化剂和肠道微生物群之间的相互作用在103项动物研究中被探索.
结论:
- 氧化应激与IBD中的炎症密切相关,尽管主要触发因素尚不清楚.
- 虽然动物研究表明抗氧化剂具有前景,但人类数据很少,这凸显了进一步临床研究的关键需求.
- 抗氧化疗法,特别是那些涉及天然化合物的抗氧化疗法,需要对IBD管理进行进一步的研究.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
317
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
317
Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


